X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (63286) 63286
Book Review (14270) 14270
Publication (5425) 5425
Newsletter (2436) 2436
Newspaper Article (497) 497
Magazine Article (438) 438
Conference Proceeding (314) 314
Book Chapter (293) 293
Book / eBook (134) 134
Transcript (85) 85
Trade Publication Article (67) 67
Web Resource (63) 63
Dissertation (20) 20
Streaming Video (17) 17
Data Set (14) 14
Government Document (5) 5
Journal / eJournal (4) 4
Reference (3) 3
Paper (2) 2
Presentation (2) 2
Report (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (54794) 54794
humans (53343) 53343
antiviral agents - therapeutic use (38485) 38485
female (23382) 23382
male (23280) 23280
antiviral agents (21230) 21230
adult (17837) 17837
middle aged (15547) 15547
animals (10760) 10760
health aspects (10465) 10465
treatment outcome (10410) 10410
infectious diseases (9671) 9671
hiv (8985) 8985
hepatitis c, chronic - drug therapy (8370) 8370
pharmacology & pharmacy (8257) 8257
infection (8236) 8236
antiviral agents - pharmacology (8223) 8223
virology (8105) 8105
drug therapy, combination (7873) 7873
hiv infections - drug therapy (7755) 7755
gastroenterology & hepatology (7611) 7611
interferon-alpha - therapeutic use (7326) 7326
aged (7063) 7063
drug therapy (7024) 7024
immunology (6679) 6679
ribavirin - therapeutic use (6321) 6321
hepatitis c (6215) 6215
therapy (6206) 6206
analysis (6129) 6129
viruses (6022) 6022
antiviral agents - administration & dosage (5765) 5765
care and treatment (5752) 5752
research (5717) 5717
virus diseases (5566) 5566
microbiology (5410) 5410
interferon (5302) 5302
infections (5155) 5155
hepatitis c virus (5148) 5148
abridged index medicus (5117) 5117
antiviral agents - adverse effects (5033) 5033
viral load (5010) 5010
risk factors (4979) 4979
adolescent (4963) 4963
hepatitis (4575) 4575
genotype (4474) 4474
hepatitis c - drug therapy (4471) 4471
hepacivirus - genetics (4390) 4390
aids (4382) 4382
aids/hiv (4364) 4364
human immunodeficiency virus--hiv (4321) 4321
ribavirin (4279) 4279
hiv infection (4262) 4262
hepatitis b, chronic - drug therapy (4023) 4023
mice (4004) 4004
retrospective studies (3951) 3951
anti-hiv agents - therapeutic use (3835) 3835
recombinant proteins (3811) 3811
young adult (3744) 3744
child (3695) 3695
highly active antiretroviral therapy (3647) 3647
time factors (3607) 3607
medicine, general & internal (3535) 3535
virus-infection (3363) 3363
acyclovir - therapeutic use (3342) 3342
antiretroviral therapy (3335) 3335
polyethylene glycols - therapeutic use (3254) 3254
medicine (3194) 3194
research article (3159) 3159
transplantation (3086) 3086
virus replication - drug effects (3070) 3070
hepacivirus - drug effects (3018) 3018
prevention (2968) 2968
medical research (2935) 2935
hepatitis b (2899) 2899
disease (2876) 2876
human-immunodeficiency-virus (2811) 2811
article (2787) 2787
dosage and administration (2782) 2782
influenza (2770) 2770
replication (2761) 2761
virus (2735) 2735
mortality (2714) 2714
antiviral activity (2679) 2679
hiv infections - complications (2655) 2655
in-vitro (2636) 2636
antiviral therapy (2625) 2625
antiretroviral drugs (2565) 2565
liver (2556) 2556
hepatitis c, chronic - virology (2548) 2548
influenza, human - drug therapy (2482) 2482
multidisciplinary sciences (2465) 2465
drug resistance (2460) 2460
rna (2449) 2449
human immunodeficiency virus (2429) 2429
prospective studies (2406) 2406
recurrence (2398) 2398
drug resistance, viral (2375) 2375
child, preschool (2371) 2371
patients (2363) 2363
hiv infections - virology (2350) 2350
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (89) 89
Online Resources - Online (62) 62
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
UofT at Mississauga - Stacks (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
UofT at Scarborough - Stacks (4) 4
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Bindery (1) 1
Gerstein Science - Periodical Stacks (1) 1
Gerstein Science - Processing (1) 1
Media Commons - Audio Visual (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Government Pubs (1) 1
Scarborough Hospital - Hospital Department (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (61794) 61794
French (1057) 1057
Chinese (769) 769
Spanish (722) 722
German (719) 719
Russian (624) 624
Japanese (439) 439
Polish (182) 182
Italian (153) 153
Korean (110) 110
Dutch (105) 105
Hungarian (101) 101
Danish (50) 50
Romanian (48) 48
Portuguese (46) 46
Swedish (34) 34
Czech (32) 32
Finnish (30) 30
Croatian (27) 27
Hebrew (24) 24
Turkish (24) 24
Ukrainian (23) 23
Norwegian (20) 20
Serbian (17) 17
Bulgarian (15) 15
Slovak (7) 7
Arabic (5) 5
Lithuanian (4) 4
Bosnian (2) 2
Icelandic (2) 2
Afrikaans (1) 1
Albanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2011, ISBN 9780470934685, xiii, 438 p., [16] p. of plates
This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the... 
Antiviral agents
Book
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 3, pp. 216 - 224
Journal Article
2001, ISBN 9781555811563, x, 359
Book
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 58, Issue 7, pp. 928 - 936
Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs... 
sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | POTENT | BI 201335 | HIV | INHIBITOR | ANTIRETROVIRAL TREATMENT | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Hepacivirus | Sofosbuvir | Economic aspects | Antiviral agents | Production management | Care and treatment | Hepatitis C | Hepatitis | Antiviral drugs | Medical treatment | Developing countries--LDCs | Index Medicus | and Commentaries
Journal Article